{
    "Trade/Device Name(s)": [
        "UniCel DxC SYNCHRON Systems Glucose Reagent (GLUH)"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K131189",
    "Predicate Device Reference 510(k) Number(s)": [
        "K883181"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CFR"
    ],
    "Summary Letter Date": "April 11, 2014",
    "Summary Letter Received Date": "April 14, 2014",
    "Submission Date": "April 4, 2014",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma",
        "Urine",
        "Cerebrospinal fluid"
    ],
    "Specimen Container(s)": [
        "Lithium Heparin tube",
        "Sodium Heparin tube",
        "Potassium Oxalate/Sodium Fluoride tube"
    ],
    "Instrument(s)/Platform(s)": [
        "UniCel DxC 600 SYNCHRON System",
        "UniCel DxC 800 SYNCHRON System"
    ],
    "Method(s)/Technology(ies)": [
        "Timed endpoint spectrophotometric assay",
        "Hexokinase enzymatic method"
    ],
    "Methodologies": [
        "Quantitative chemistry assay"
    ],
    "Submission Type(s)": [
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for UniCel DxC SYNCHRON Systems Glucose Reagent (GLUH) for quantitative measurement of glucose in human serum, plasma, urine, or CSF using hexokinase method on SYNCHRON analyzers.",
    "Indications for Use Summary": "Intended for quantitative determination of glucose in human serum, plasma, urine, or CSF to aid in diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, idiopathic hypoglycemia, and pancreatic islet cell carcinoma.",
    "fda_folder": "Clinical Chemistry"
}